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Abstract
Background: Renalase is a soluble enzyme that metabolizes circulating catecholamines. A common missense polymorphism
in the flavin-adenine dinucleotide-binding domain of human renalase (Glu37Asp) has recently been described. The
association of this polymorphism with cardiac structure, function, and ischemia has not previously been reported.
Methods: We genotyped the rs2296545 single-nucleotide polymorphism (Glu37Asp) in 590 Caucasian individuals and
performed resting and stress echocardiography. Logistic regression was used to examine the associations of the Glu37Asp
polymorphism (C allele) with cardiac hypertrophy (LV mass.100 g/m2), systolic dysfunction (LVEF,50%), diastolic
dysfunction, poor treadmill exercise capacity (METS,5) and inducible ischemia.
Results: Compared with the 406 participants who had GG or CG genotypes, the 184 participants with the CC genotype had
increased odds of left ventricular hypertrophy (OR=1.43; 95% CI 0.99–2.06), systolic dysfunction (OR=1.72; 95% CI 1.01–
2.94), diastolic dysfunction (OR=1.75; 95% CI 1.05–2.93), poor exercise capacity (OR=1.61; 95% CI 1.05–2.47), and inducible
ischemia (OR=1.49, 95% CI 0.99–2.24). The Glu37Asp (CC genotype) caused a 24-fold decrease in affinity for NADH and a
2.3-fold reduction in maximal renalase enzymatic activity.
Conclusions: A functional missense polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, ventricular
dysfunction, poor exercise capacity, and inducible ischemia in persons with stable coronary artery disease. Further studies
investigating the therapeutic implications of this polymorphism should be considered.
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Introduction
The kidney, in addition to maintaining fluid and electrolyte
homeostasis, performs essential endocrine functions [1]. Patients
with end-stage renal disease are at high risk for cardiovascular
events, even when provided optimal renal replacement therapy
[2,3]. It has been suggested that failure to replicate the endocrine
functions of the kidney may contribute to this risk, in association
with heightened sympathetic tone [4,5,6]. We recently identified
renalase, a flavin adenine dinucleotide-dependent amine oxidase
that is secreted into the blood by the kidney, metabolizes
circulating catecholamines, and is deficient in chronic kidney
disease [7]. Excess catecholamines promote the activity, secretion,
and synthesis of renalase, providing a novel pathway of negative-
feedback homeostatic control [8]. In rodents, parenteral admin-
istration of renalase lowers blood pressure, heart rate, and cardiac
contractility [9]. During cardiac ischemia in rats, infusion of
recombinant renalase reduces myocardial infarct size whereas
neonatal nephrectomy leads to elevated sympathetic nervous
system activity, renalase deficiency, and cardiac hypertrophy
[10,11].
Human renalase is encoded by a 311Kbp gene with 10 exons
located on chromosome 10q23.33. The renalase protein is well
conserved with orthologs present in chimpanzees (95% amino acid
identity) and cyanobacteria (23% identity). The major isoform of
renalase contains 342 amino acids comprising a signal peptide
(amino acids 1–17), a flavin-adenine dinucleotide (FAD) binding
domain (amino acids 4–45), and a monoamine oxidase domain
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tively-spliced isoforms of renalase [12]. The most common isoform
(renalase1) is encoded by exons 1–4, 6–7, and 9. It is the
predominant human renalase protein detectable in plasma,
kidney, heart, skeletal muscle, and liver. The functional signifi-
cance of the spliced isoforms is not known. A common missense
polymorphism in the flavin-adenine dinucleotide-binding domain
of human renalase (Glu37Asp) has recently been described. This is
the only reported common coding single-nucleotide polymorphism
in the renalase gene, and was recently found to be associated with
essential hypertension [13].
Whether common genetic variation at this locus affects cardiac
structure, function, and ischemia in humans is not known. We
therefore genotyped the (Glu37Asp) polymorphism and evaluated
its association with cardiovascular phenotypes in a large cohort of
individuals with stable coronary artery disease.
Methods
Participants
The Heart and Soul Study is a prospective cohort study
investigating the influence of psychosocial factors on cardiovascu-
lar events in outpatients with stable coronary artery disease. The
enrollment process for the Heart and Soul Study has been
previously described [14]. Eligible participants were recruited
from outpatient clinics in the San Francisco Bay Area if they met
at least one of the following inclusion criteria: 1) history of
myocardial infarction, 2) angiographic evidence of at least 50%
stenosis by area in at least 1 coronary artery, 3) evidence of
exercise-induced ischemia by treadmill electrocardiogram or stress
nuclear perfusion imaging, or 4) history of coronary revascular-
ization. Individuals were excluded if they had a history of
myocardial infarction in the past 6 months, deemed themselves
unable to walk 1 block, or if they were planning to move out of the
local area within 3 years. There was no exclusion on the basis of
kidney disease.
The study protocol was approved by the following Institutional
Review Boards: the University of California San Francisco
Committee on Human Research, the Research and Development
Committee at the San Francisco VA Medical Center, the Medical
Human Subjects Committee at Stanford University, the Human
Subjects Committee at the VA Palo Alto Health Care System, and
the Data governance Board of the Community Health Network of
San Francisco. All participants provided written informed consent.
Between September 2000 and December 2002, a total of 1024
participants enrolled in the study. Of these, DNA samples were
available for analysis in 982 individuals, including 590 of
Caucasian ethnicity. There were no demographic differences
between individuals who did and those who did not provide DNA
samples for analysis.
Genotyping
Prior to the study appointment, participants completed an
overnight fast except for taking their regularly prescribed
medications. Fasting venous blood samples were drawn into
chilled ethylene-diamine-tetra-acetic acid tubes, and peripheral
blood leukocytes were stored at 270u Celsius. Samples were later
thawed, and genomic DNA was extracted using a salt modification
method (Gentra Systems). The ABI PRISM 7900HT Sequence
Detection System was used to perform genotyping of the
rs2296545 single nucleotide polymorphism using the 59nuclease
allelic discrimination assay (Taqman Assay, Applied Biosystems,
Foster City, USA). The assay kit included the forward and reverse
target-specific polymerase chain reaction primers, and the Taq-
man MGB probes labeled with dyes DFAM and VIC. The total
volume of the sequencing reaction was 5-ul containing 2.5ul of
Taqman Universal PCR Master Mix, 0.083ul of 40X Taqman
MGB Assay Mix, 1.417ul of ddH2O, and 1ul (5 ng) of genomic
DNA. Investigators blinded to the clinical data performed the
genotyping assays.
Cardiac Structure, Function, and Ischemia
All participants underwent complete resting 2-dimensional
echocardiography and Doppler examination using an Acuson
Sequoia ultrasound system (Siemens Medical Solutions, Mountain
View, CA) with a 3.5-MHz transducer. Standard parasternal
short-axis and apical 2 – and 4-chamber views were obtained and
planimetered to determine end-diastolic and end-systolic volumes.
The left ventricular ejection fraction (LVEF) was calculated as (end
diastolic volume – end systolic volume)/end diastolic volume.
Systolic dysfunction was defined as LVEF,50%. Diastolic
dysfunction was defined as the presence of one of the following:
pseudonormal transmitral inflow pattern defined as a ratio of peak
mitral early diastolic to atrial contraction velocity (E/A) of
0.75,E/A,1.5 with diastolic dominant pulmonary vein flow;
restrictive filling defined as an E/A of 1.5 or greater with diastolic
dominant pulmonary vein flow [15]. Left ventricular mass was
calculated using a truncated ellipsoid equation as previously
validated [16]. Left ventricular hypertrophy was defined as LV
mass index.100 g/m
2.
All participants then underwent a symptom-limited graded
exercise treadmill test according to a standard Bruce protocol. To
achieve maximal heart rate, participants who were unable to
continue the standard Bruce protocol were switched to lower
manual settings on the treadmill and encouraged to exercise for as
long as possible. Maximal exercise capacity in metabolic
equivalents (METS) was determined at peak exercise. Poor
exercise capacity was defined as,5 METS at peak exercise [17].
Inducible ischemia was defined as the presence of one or more
new wall motion abnormalities occurring with exercise. The post-
exercise wall motion score was calculated according to the
American Society of Echocardiography guidelines [18]. Resting
and stress echocardiograms were read by a single, experienced
reader (N.B.S.) who was blinded to genotype and outcome data.
Other Patient Characteristics
Baseline demographics, age, sex, and ethnicity were determined
by self-reported questionnaire. Cardiovascular co-morbidities
including hypertension, diabetes, hyperlipidemia, prior myocardial
infarction, prior congestive heart failure, prior stroke, smoking
status, and prior revascularization were determined by self-report.
Recumbent blood pressure was measured after 5 minutes at rest.
Participants were weighed and measured without shoes. Body
Mass Index (BMI) was calculated as the ratio of mass (kg) to the
square of height (m
2). All participants were instructed to bring
their medication bottles to the study appointment where study
personnel recorded all current medications. Medications were
categorized using Epocrates Rx (San Mateo, CA), an electronic
reference database that contains 3300 drugs classified by both
generic and commercial product names. Fasting serum chemistry
samples were used to measure triglycerides, HDL cholesterol, LDL
cholesterol. Serum creatinine was measured by the rate Jaffe
method. The intra-individual coefficient of variation was 2%.
Estimated glomerular filtration rate (GFR) was calculated by
the abbreviated (4-variable) Modification of Diet and Renal
Disease Study formula as follows: estimated GFR=186x(serum
creatinine
21.154)x(age
20.203)x(0.742 if female)x(1.21 if black) [19].
Renalase
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Glu37 and Asp37
Untagged,recombinant renalase variants, Glu37 and Asp37,
were generated by cloning the respective coding region into the
Ned1/Xho1 sites of the Pet27b+ vector (Novagen, Madison, WI).
E. coli BL21 were transformed and grown at 37uC for 16 hours
with 0.1 mM flavin adenine dinucleotide (FAD). Isopropyl b-D-1-
thiogalactopyranoside (IPTG) was added for the last 3.5 hours of
culture. Recombinant renalase was purified from inclusion bodies
and refolded as previously described [7].
Since renalase is a NADH/FAD dependent oxidoreductase, the
enzymatic activity the each variant was assessed by measuring the
rate of reduction of 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfophenyl)-2H tetrazolium monosodium salt (WST-1) as a
function of NADH concentration. Reduction of WST-1 results in
the formation of a yellow, water-soluble formazan product, which
can be quantified by measuring absorbance at 450 nm [20,21].
The assay buffer contained 50 mM potassium phosphate, 0.5 mM
WST-1 (Dojindo Molecular Technologies, Inc), 1 mM EDTA,
pH 7.5. NADH concentration was varied from 0 to 2 mM. The
reactions were initiated by adding 20 mg of 37Glu, or 37Asp, or
bovine serum albumin (BSA) as a negative control, in a total
volume of 200 ml, in 96-well plate cuvettes (0.6 cm path length).
Changes in absorbance at 37uC were recorded every minute for 15
minutes. The amount of WST-1 reduced by renalase was
calculated from the increase in absorbance at 450 nm, and using
a molar extinction coefficient of 37,000 M
21 cm-. Background
correction was achieved by subtracting the changes in absorbance
obtained with BSA. To estimate kinetics parameters, initial
velocity was plotted against NADH concentration, and the data
were fitted to the Michaelis-Menten equation using non-linear
regression (GraphPad Prism, GraphPad Software, Inc.).
Statistical Analysis
Differences in baseline characteristics between participants with
distinct rs2296545 genotypes (GG, GC, and CC) were compared
with the use of analysis of variance for continuous variables and
the chi-squared test for dichotomous variables. We then examined
differences in cardiac phenotype by genotype using generalized
linear models for continuous measures and logistic regression for
dichotomous measures of cardiac function. Participants with GG
and GC genotypes were combined for multivariable analyses
because they had similar cardiac function in unadjusted analyses.
Multivariable adjustment was made for age, gender, BMI, systolic
blood pressure, diastolic blood pressure, and estimated GFR.
Covariates were selected on their potential for confounding or
mediating effects. Model assumptions were checked by visual
inspection of directed acyclic graphs [22]. To explore the
possibility of effect modification by age, we tested for statistical
interactions between renalase genotype and measures of cardio-
vascular structure and function in the multivariable adjusted
models.
Statistical analysis was performed using SAS software version
9.1 (SAS Institute Inc, Cary, NC). The authors take responsibility
for the integrity of the data. All authors had full access to the data,
except N.B.S. who was blinded to the genotype data. All authors
have read and agree to the manuscript as written.
Results
We genotyped 590 Caucasian subjects in the Heart and Soul
Study for the rs2296545 (Glu37Asp) single-nucleotide polymor-
phism. The genotype distribution was GG (107), CG (299), and
CC (184). The observed frequencies of the G and C alleles were
0.43 and 0.57 respectively. These findings were consistent with
Hardy-Weinberg equilibrium (p=0.99). In a Han Chinese
population, the observed frequencies of the G and C alleles were
0.39 and 0.61 in hypertensive individuals, and 0.44 and 0.56 in
controls respectively [13]. The baseline characteristics of the study
population categorized by genotype at rs2296545 are shown in
Table 1. There were no significant associations between
rs1333049 genotype and baseline demographics, medical history,
smoking, medication use, blood pressure, or lipids. In bivariate
analysis, GG homozygosity was associated with a prior history of
revascularization (p=0.04).
Parameters of cardiovascular structure, function, and ischemia
categorized by genotype at rs2296545 are shown in Table 2. The
CC homozygous genotype was associated with lower ejection
fraction (p=0.01), higher left ventricular mass index (p=0.008),
lower exercise capacity (p=0.002), and more diastolic dysfunction
(p=0.05). There was a trend towards more inducible ischemia in
the CC group (p=0.09). After multivariable adjustment the CC
homozygous genotype remained associated with lower ejection
fraction (p=0.01), higher left ventricular mass index (p=0.01),
and lower exercise capacity (p=0.003) (Table 3).
In logistic regression models adjusted for age, demographics,
BMI, systolic and diastolic blood pressure, and estimated GFR, the
CC genotype was associated with left ventricular hypertrophy
(OR=1.43, 95% CI 0.99–2.06; p=0.06), systolic dysfunction
(OR=1.72, 95% CI 1.01–2.94; p=0.05), diastolic dysfunction
(OR=1.75, 95% CI 1.05–2.93; p=0.03), poor exercise capacity
(OR=1.61, 95% CI 1.05–2.47; p=0.03), and inducible ischemia
(OR=1.49, 95% CI 0.99–2.24; p=0.06) (Table 4). The
proportion of participants with abnormal cardiovascular pheno-
type classified by genotype at rs2296545 is shown in Figure 1. We
found no evidence that the association of renalase genotype with
cardiovascular structure and function was modified by age (all p
values for interaction.0.2).
Renalase is a FAD dependent oxidoreductase, which uses NADH
as a cofactor to reduce its FAD moiety. In the presence of oxygen the
reduced renalase-FADH complex metabolizes subtrates such as
catecholamines. Renalase has intrinsic NADH oxidase activity since,
in the absence of substrates, it can convert NADH to NAD+ and
generate superoxide anion as a byproduct. To test if the Glu37Asp
polymorphism had any detectable functional consequence, we
compared the NADH oxidase activity of the Glu37 and Asp37
variants of the recombinant renalase by measuring the rate of
reduction, of the electron acceptor WST-1, as a function of NADH
concentration. At all NADH concentrations tested (up to 2 mM,)
Glu37 metabolized NADH at a significantly faster rate than Asp37.
Figure 2 depicts the results of a representative experiment with a
NADH concentration of 400 mM. Kinetics parameters were deter-
mined by fitting (non linear regression) initial rate data to the
Michaelis-Menten equation. The Glu37Asp mutation caused a 24 fold
increase in Km (Glu37= 34.164.0 mM; Asp37=8206115.1 mM,
p,0.000001, n=3), and a 2.3 fold reduction in Vmax (Glu37=
58.361.1 nmol/min/mg; Asp37=25.461.6 nmol/min/mg, p,
0.0001, n=3).; Figure 3.
Discussion
The recent discovery of renalase has elucidated a novel pathway
for the homeostatic control of circulating catecholamines. Data
from the International HapMap Consortium has identified a single
common non-synonymous single-nucleotide polymorphism in the
human renalase gene that results in an aspartic acid to glutamic
acid substitution at codon 37 (Glu37Asp) in the flavin-adenine
dinucleotide-binding site. In the present study of 590 persons with
Renalase
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(Asp/Asp) homozygosity at codon 37 with cardiac hypertrophy,
dysfunction, and ischemia. Although this is a conservative
substitution (Glu37Asp), it does occur in a critical region of the
protein, namely the FAD binding domain, And it is, therefore, not
surprising that compared to Glu37, Asp37 has a significantly lower
affinity for NADH and a reduced maximal velocity. These findings
raise the intriguing possibility that decreased activity of the enzyme
renalase may contribute to cardiovascular disease.
At baseline, renalase activity in blood mirrors sympathetic tone
[8]. Brief surges in catecholamine levels increase the activity,
secretion, and synthesis of renalase resulting in accelerated
Table 1. Baseline characteristics of participants by genotype at rs2296545.
Variable
GG
(Glu/Glu)
N=107
CG
(Glu/Asp)
N=299
CC
(Asp/Asp)
N=184
P value
(ANOVA or chi
2)
Age 67610 68611 68612 .89
Male (%) 89(83) 248(83) 163(89) .22
BMI (kg/m2) 28.464.6 28.565.4 28.765.1 .88
Medical History (%)
Hypertension 65(61) 196(66) 125(68) .46
Myocardial infarction 60(56) 166(56) 103(56) 1.0
CHF 16(15) 46(15) 43(24) .06
Stroke 10(9) 38(13) 28(15) .35
Diabetes 22(21) 56(19) 43(23) .48
Revascularization 80(75) 184(62) 116(63) .04
Current Smoking 18(17) 45(15) 37(20) .35
Medication Use (%)
Statin 71(66) 200(67) 115(63) .60
Beta-blocker 59(55) 174(58) 103(56) .82
Aspirin 86(80) 235(79) 139(76) .59
ACE-I/ARB 57(53) 151(51) 99(54) .75
Systolic BP (mmHg) 130.3622.5 131.1620.1 131.6620.0 .87
Diastolic BP (mmHg) 72.9611.1 73.3610.7 73.2611.3 .94
Triglycerides (mg/dL) 140.8696.9 149.26150.2 144.06130.7 .83
LDL-Cholesterol (mg/dL) 97.5630.8 104.8634.9 102.1632.6 .16
HDL-Cholesterol (mg/dL) 43.6612.0 45.4615.1 46.1615.7 .36
Creatinine (mg/dL) 1.160.3 1.160.3 1.160.5 .09
Estimated GFR (ml/min) 79.0625.2 81.4626.8 78.4629.7 .49
doi:10.1371/journal.pone.0013496.t001
Table 2. Parameters of cardiovascular structure and function
by genotype at rs2296545 (amino acid 37).
Genotype
Variable
GG
(Glu/Glu)
N=107
GC
(Glu/Asp)
N=299
CC
(Asp/Asp)
N=184
P value
for trend
LVEF (%) 60.969.2 62.669.0 59.8611.4 0.01
LV Mass Index (g/m2) 96.6622.6 94.3624.7 101.7626.5 0.008
Exercise Capacity
(METS)
7.863.9 7.763.4 6.663.3 0.002
Diastolic Dysfunction
(%)
14(15) 28(11) 32(19) 0.05
Inducible Ischemia (%) 21(21) 73(26) 57(33) 0.09
doi:10.1371/journal.pone.0013496.t002
Table 3. Association of CC (vs. GG or CG) genotype at
rs2296545 with continuous measures of cardiovascular
structure and function.
Mean (±SE)
CC
(Asp/Asp)
N=184
GC or GG
(Glu/Asp or Glu/Glu)
N=406
P
value
LVEF (%)
Adjusted for age and gender 60.8(0.85) 63.0(0.62) 0.01
Multivariable adjusted * 60.7(0.86) 63.0(0.62) 0.01
LV Mass Index (g/m2)
Adjusted for age and gender 96.3(2.11) 90.3(1.53) .006
Multivariable adjusted * 95.4(2.10) 90.0(1.53) .01
Exercise Capacity (METS)
Adjusted for age and gender 6.0(0.28) 7.2(0.21) .0001
Multivariable adjusted * 6.2(0.27) 7.2(0.20) .0003
Adjusted for age, gender, body mass index, systolic blood pressure, diastolic
blood pressure and estimated glomerular filtration rate.
doi:10.1371/journal.pone.0013496.t003
Renalase
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nism. In animal models, catecholamine regulation by renalase
demonstrates significant hemodynamic effects that mimic nonse-
lective beta-adrenoceptor blockade: reduced heart rate, blood
pressure, and cardiac contractility [7]. However, studies examin-
ing the in vivo relevance of renalase in humans are lacking. In a
large case-control study of a northern Han Chinese population,
Zhao et al found an association of the (Glu37Asp) polymorphism
with essential hypertension (odds ratio 1.61; 95% CI 1.26–2.04;
p=0.0002) [13]. By contrast we found no significant association of
the (Glu37Asp) polymorphism with either systolic or diastolic
blood pressure, possibly because of more aggressive blood pressure
control in patients with coronary artery disease. This discrepancy
may reflect differences in study populations (essential hypertension
versus stable coronary artery disease) and commensurate differ-
ences in medication use.
Accumulating evidence implicates excessive circulating cate-
cholamines in the pathogenesis of left ventricular hypertrophy, a
powerful independent risk factor for cardiovascular death and
morbidity [23,24,25]. The observation that left ventricular
hypertrophy is common in patients with end-stage renal disease
has suggested a link between kidney function and cardiac
hypertrophy [26,27,28]. Ghosh et al recently demonstrated that
neonatal nephrectomy in rats results in cardiac hypertrophy
associated with decreased norepinephrine metabolism [11].
Notably, renalase protein expression in cardiac tissue from
nephrectomized rats was significantly lower than in controls. In
the present study, we found an association of Asp/Asp
homozygosity at codon 37 with increased left ventricular mass
index (multivariable adjusted effect size=+5.4 g/m
2). This
supports a mechanistic link between the renalase-catecholamine
axis and left ventricular hypertrophy, and extends this finding to
Figure 1. Proportion of participants with abnormal cardiovascular phenotype classified by genotype at rs2296545 (p,0.05 for all
comparisons).
doi:10.1371/journal.pone.0013496.g001
Table 4. Association of CC (vs. GG or CG) genotype at rs2296545 with dichotomous measures of cardiovascular structure and
function.
OUTCOME
Adjusted for
age and gender
OR (95% CI) p
Multivariable adjusted*
OR (95% CI) p
Systolic Dysfunction
(LVEF,50%)
1.64 (0.97–2.78) .06 1.72 (1.01–2.94) .05
Left Ventricular Hypertrophy (LVMI.100 g/m2) 1.48 (1.03–2.12) .04 1.43 (0.99–2.06) .06
Diastolic Dysfunction 1.76 (1.07–2.92) .03 1.75 (1.05–2.93) .03
Inducible Ischemia 1.48 (0.99–2.22) .06 1.49 (0.99–2.24) .06
Poor Exercise Capacity
(,5 METS)
1.67 (1.09–2.54) .02 1.61 (1.05–2.47) .03
*Adjusted for age, gender, body mass index, systolic blood pressure, diastolic blood pressure and estimated glomerular filtration rate.
doi:10.1371/journal.pone.0013496.t004
Renalase
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investigate the relative contributions of renalase secreted from the
kidney and the heart to the inhibition of cardiac hypertrophy.
The association of the Glu37Asp polymorphism with cardiac
dysfunction has not previously been reported. Renalase infusion in
rats results in an increase in stroke volume, which may reflect a
compensatory response to decreased heart rate. However, since
renalase also reduces cardiac contractility, an alternative explana-
tion is that renalase-induced metabolism of circulating catechol-
amines increases cardiac lusitropy and optimizes diastolic-systolic
coupling. We found essentially similar odds ratios for both systolic
and diastolic dysfunction associated with Asp/Asp homozygosity
in multivariable adjusted models further suggesting an influence of
the renalase-catecholamine axis on both aspects of cardiac
function. Detailed hemodynamic studies examining the effects of
renalase administration on diastolic function would be of interest
in this regard.
Cardiac ischemia, whether acute or chronic, is associated with a
significant elevation in circulating catecholamines that promote
and exacerbate myocardial infarction [29]. Pharmacologic
blockade of beta adrenoceptors has therefore become an essential
component of medical therapy for acute coronary syndromes and
chronic stable angina [30,31,32,33]. Since renalase specifically
metabolizes circulating catecholamines, we sought to determine
whether common variation in the renalase gene is associated with
inducible ischemia in persons with stable coronary artery disease.
Homozygosity for Asp/Asp at codon 37 was associated with
inducible wall motion abnormalities during stress echocardiogra-
phy (OR 1.5) as well as reduced exercise tolerance (multivariable
adjusted effect size=21.0 METS). These findings extend the
observation that, in rats, recombinant renalase reduced myocar-
dial infarction size by 54% [10]. Taken together, these data
suggest that renalase deficiency or loss of function may contribute
to the ischemic cascade in myocardium. Whether renalase
replacement therapy can reduce myocardial ischemia in persons
with coronary artery disease is not known. We speculate that
experimental studies addressing this question may have therapeu-
tic implications in this population.
The main strength of the present study is the collection of
detailed phenotypic data derived from comprehensive resting and
stress echocardiography in all participants. Combined with the a
priori selection of the only known common coding polymorphism
in renalase, the genotype-phenotype associations reported are
biologically plausible and unlikely to represent false positive
associations [34]. In addition, confounding by renal impairment is
unlikely given the normal mean estimated GFR of study
participants. However, several important limitations should be
considered in the interpretation of our results. First, our study
population was restricted to Caucasian individuals, predominantly
men. Therefore, our results may not be generalized to women or
to other racial groups, and should be replicated in other
populations. Second, we did not measure serum renalase levels
or activity as an intermediate phenotype. Finally, our analysis of
diastolic dysfunction did not incorporate newer echocardiographic
techniques such as tissue Doppler imaging, which would offer
further refinement and resolution of phenotype [35].
In conclusion, we found an association of the renalase
Glu37Asp polymorphism (C allele) with cardiac hypertrophy,
dysfunction, and ischemia in a cross-sectional study of individuals
with stable coronary artery disease and normal renal function. The
renalase pathway is a novel regulator of circulating catecholamine
levels. Future studies should be aimed at determining whether
there is a potential therapeutic role for renalase replacement in
persons at high risk of cardiovascular morbidity and mortality.
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Figure 2. Enzymatic activity and kinetics parameters of
renalase variants. Change in absorbance reflects the rate of WST-1
reduction, which is index of NADH oxidation; Glu37: glutamic acid at
amino acid 37; Asp37: aspartic acid at amino acid 37; BSA, bovine serum
albumin; raw data shown for a single experiment.
doi:10.1371/journal.pone.0013496.g002
Figure 3. Calculated kinetics parameters: Glu37= 34.164.0 mM;
Asp37=8206115.1 mM, p,0.000001, n=3; Vmax : Glu37=
58.361.1 nmol/min/mg; Asp37=25.461.6 nmol/min/mg, p,0.0001,
n=3; Km: substrate concentration required to reach K maximal
velocity; Vmax: maximal velocity; V= velocity.
doi:10.1371/journal.pone.0013496.g003
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